38 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
)
Assets classified as held for sale (note 16)
Total Current Assets
Non-Current Assets
Property and equipment, net (note 6)
Other assets (notes 7 & 9 … and other liabilities (note 8)
Liability classified as held for sale (note 16)
Total Current Liabilities
Non-Current Liabilities
Other long-term
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
of this manufacturing plant space and lease such space to third parties for a period of approximately three years, all plant related expenses were classified
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable … had not paid any royalties to the IIA.
NOTE 10 – EQUITY
All Company warrants are classified as a component of shareholders’ equity because
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
and diversification. The Company from time-to-time invests a portion of its excess cash in mutual funds that are classified based on the nature … , 2023 (UNAUDITED)
NOTE 11 – EQUITY
All Company warrants are classified as a component of shareholders’ equity because such warrants are free standing
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
space and to lease such space to potential clients for a period of approximately three years, all plant related expenses were classified … $7.1 of our cash was classified as a long-term interest-bearing bank deposit, resulting in total working capital and deposits which mature within
6-K
EX-99.2
f4wsh97yedmaywz2bwu3
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
xgrxtbd7kd4
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
q8elai 3p
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
sxwic56052
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
0q55p3m 80xoeqbeuq9
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
cndap1r
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
jfbnopno1b
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
12t1cwd0
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
d1xnym ge0dskir9
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
cuh339n9ltk1q85i69ik
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
wojb bcu80
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K/A
EX-99.1
r5bszq74hurkerlugesu
13 Oct 20
Condensed Consolidated Financial Statements
9:16am